Edition:
India

Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration With Bristol-Myers Squibb


Monday, 8 Jan 2018 

Jan 8 (Reuters) - Five Prime Therapeutics Inc ::FIVE PRIME THERAPEUTICS EARNS IND MILESTONE PAYMENT UNDER IMMUNE CHECKPOINT PATHWAYS DISCOVERY COLLABORATION WITH BRISTOL-MYERS SQUIBB AND ANNOUNCES THAT BMS HAS EXTENDED THE RESEARCH TERM OF THIS COLLABORATION FOR A SECOND TIME.FIVE PRIME THERAPEUTICS INC - MILESTONE FOR ANTIBODY TARGETING TIM-3 TRIGGERS $5 MILLION PAYMENT TO FIVE PRIME.FIVE PRIME- BMS EXTENDS RESEARCH COLLABORATION TERM FOR DEVELOPMENT, COMMERCIALIZATION FOR THERAPEUTICS IN 3 IMMUNE CHECKPOINT PATHWAYS TO MARCH 2019.FIVE PRIME THERAPEUTICS INC - BRISTOL-MYERS SQUIBB WILL ALSO PROVIDE ADDITIONAL FUNDING TO FIVE PRIME FOR EXTENDED TERM OF RESEARCH COLLABORATION. 

Company Quote

6.63
0.19 +2.95%
9:53pm IST